PT3426237T - Método para tratar atrofia cerebral - Google Patents

Método para tratar atrofia cerebral

Info

Publication number
PT3426237T
PT3426237T PT177160678T PT17716067T PT3426237T PT 3426237 T PT3426237 T PT 3426237T PT 177160678 T PT177160678 T PT 177160678T PT 17716067 T PT17716067 T PT 17716067T PT 3426237 T PT3426237 T PT 3426237T
Authority
PT
Portugal
Prior art keywords
treating brain
brain atrophy
atrophy
treating
brain
Prior art date
Application number
PT177160678T
Other languages
English (en)
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of PT3426237T publication Critical patent/PT3426237T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT177160678T 2016-03-08 2017-03-08 Método para tratar atrofia cerebral PT3426237T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2016/050160 WO2017155386A1 (en) 2016-03-08 2016-03-08 Method for treating brain atrophy

Publications (1)

Publication Number Publication Date
PT3426237T true PT3426237T (pt) 2023-11-17

Family

ID=55863158

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177160678T PT3426237T (pt) 2016-03-08 2017-03-08 Método para tratar atrofia cerebral

Country Status (13)

Country Link
US (1) US20190076375A1 (pt)
EP (2) EP3426237B1 (pt)
JP (1) JP6980678B2 (pt)
CN (1) CN109069447A (pt)
AU (1) AU2017231577B2 (pt)
BR (1) BR112018068110A2 (pt)
ES (1) ES2962361T3 (pt)
FI (1) FI3426237T3 (pt)
HR (1) HRP20231115T1 (pt)
PL (1) PL3426237T3 (pt)
PT (1) PT3426237T (pt)
SI (1) SI3426237T1 (pt)
WO (2) WO2017155386A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7438216B2 (ja) * 2018-11-30 2024-02-26 エボニック オペレーションズ ゲーエムベーハー リン脂質と脂肪酸塩の分散体を含む調製物
JP7506473B2 (ja) 2019-12-20 2024-06-26 ポッカサッポロフード＆ビバレッジ株式会社 アミロイドβ蓄積抑制剤
WO2021167876A1 (en) * 2020-02-21 2021-08-26 Hi Llc Methods and systems for initiating and conducting a customized computer-enabled brain research study
WO2023041776A1 (en) 2021-09-17 2023-03-23 N.V. Nutricia Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1390378E (pt) * 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
US7560442B2 (en) * 2001-04-30 2009-07-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Pharmaceutically active uridine esters
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
DK1800675T3 (da) * 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
WO2009002146A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009002148A1 (en) * 2007-06-27 2008-12-31 N.V. Nutricia Food composition for prodromal dementia patients
CN102625703A (zh) * 2008-12-09 2012-08-01 费萨尔国王专科医院及研究中心 治疗神经系统疾病的孕烯醇酮硫酸盐
WO2012091542A1 (en) * 2010-12-28 2012-07-05 N.V. Nutricia Combination of components for the prevention and treatment of frailty
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013066151A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Improving recognition
WO2013129914A1 (en) * 2012-03-02 2013-09-06 N.V. Nutricia Method for improving functional synaptic connectivity
WO2013129931A1 (en) * 2012-03-02 2013-09-06 N.V. Nutricia Method for improving functional synaptic connectivity
WO2013149384A1 (en) * 2012-04-05 2013-10-10 Nippon Suisan Kaisha, Ltd. Brain atrophy prevention agent
US9650436B2 (en) * 2012-10-12 2017-05-16 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014171813A1 (en) * 2013-04-17 2014-10-23 N.V. Nutricia Nutritional composition for improving brain function in phenylketonuria
GB201405033D0 (en) * 2014-03-20 2014-05-07 Isis Innovation Combination therapy
US10166252B2 (en) * 2014-04-14 2019-01-01 N.V. Nutricia Method for assessing and treating or preventing impaired plasma polar lipid levels

Also Published As

Publication number Publication date
JP6980678B2 (ja) 2021-12-15
WO2017155396A1 (en) 2017-09-14
US20190076375A1 (en) 2019-03-14
EP3426237B1 (en) 2023-08-23
BR112018068110A2 (pt) 2019-01-15
HRP20231115T1 (hr) 2023-12-22
AU2017231577B2 (en) 2022-04-07
WO2017155386A1 (en) 2017-09-14
EP3426237A1 (en) 2019-01-16
EP3973956A1 (en) 2022-03-30
CN109069447A (zh) 2018-12-21
PL3426237T3 (pl) 2024-04-08
FI3426237T3 (fi) 2023-10-02
SI3426237T1 (sl) 2023-12-29
ES2962361T3 (es) 2024-03-18
AU2017231577A1 (en) 2018-10-25
JP2019512488A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
ZA201706616B (en) Method for treating cancer
EP3500289A4 (en) METHODS OF TREATING TRACHEOBRONCHOMALACIA
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
EP3426612B8 (en) Method for treating waste
IL257691A (en) A method for treating cancer
HK1244217A1 (zh) 用於治療蛋白質病的方法
AU2016353600B2 (en) Method for treating mucositis
HK1251965A1 (zh) 用於治療癲癇的方法
GB2567616B (en) Treatment method
HK1248133A1 (zh) 治療神經母細胞瘤的方法
HK1248135A1 (zh) 用於治療癌症的聯合方法
GB2571601B (en) Treatment method
PL2913284T3 (pl) Sposób oraz urządzenie do obróbki części
PT3426237T (pt) Método para tratar atrofia cerebral
SG11202001806TA (en) Treatment method
EP3638630C0 (en) METHOD OF TREATMENT OF MUD
IL270867A (en) Treatment method
HK1257740A1 (zh) 用於適應的方法
PL3533856T3 (pl) Sposób wytwarzania heksadekahydropirenu
SG10201508795XA (en) Method for treating cancer
HK1257072A1 (zh) 治療多發性硬化的方法
EP3246432A4 (en) Method for treating parts
GB201507268D0 (en) Method for stimulating aerogenosis